Traditional Chinese medicine composition capable of improving lung injury as well as preparation method and application of traditional Chinese medicine composition

Abstract

The invention discloses a traditional Chinese medicine composition for improving lung injury as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 5-20 parts of raw ephedra, 3-12 parts of radix sophorae flavescentis, 6-24 parts of semen armeniacae amarae, 6-24 parts of radices stellariae dichotomae and 5-20 parts of raw liquorice. Under the guidance of traditional Chinese medicine theories, dialectical treatment screening formulas are adopted, and experimental results show that the traditional Chinese medicine composition provided by the invention has good effects of relieving lung injury, relieving pulmonary edema, resisting inflammation and resisting oxidative stress, and is reliable in curative effect, good in safety and low in adverse reaction.

Description

Technical Field

[0001] The invention relates to a natural product composition, in particular to a traditional Chinese medicine composition capable of improving lung injury and a preparation method thereof. Background Art

[0002] In recent years, acute viral respiratory infectious diseases such as SARS, influenza A, and novel coronavirus infection have spread on a large scale, posing a great threat to people's lives and health. In traditional Chinese medicine theory, the above diseases belong to the category of "emerging pulmonary diseases". Traditional Chinese medicine has played a vital role in solving this type of disease problem. "Emerging pulmonary diseases" are mostly caused by the combination of "epidemic poison" and "six evils". According to traditional Chinese medicine theory, novel coronavirus infection is defined as a cold and wet plague. Therefore, in view of its pathogenesis, traditional Chinese medicine compound prescriptions with the effects of removing external pathogens, clearing heat, and drying moisture are applied to the treatment of novel coronavirus infection, such as Qingfei Paidu Decoction.

[0003] People in Northwest my country are often in a cold and dry environment due to their geographical location. Therefore, people in this region are easily affected by the cold and dry epidemics of the lung system caused by the combination of cold and dry climate and epidemic toxins. Traditional Chinese medicine has a unique therapeutic effect in the prevention and treatment of acute lung injury, with good safety and few toxic side effects. Therefore, in order to solve the health problems of the population in Northwest China, it is of great significance to select a traditional Chinese medicine compound composition with the function of improving lung injury under the guidance of traditional Chinese medicine theory. Summary of the invention

[0004] Purpose of the invention: The purpose of the present invention is to provide a Chinese medicine composition with reliable efficacy, good safety and good effect of improving lung injury. Another purpose of the present invention is to provide a preparation method and application of the above composition.

[0005] Technical solution: In order to achieve the above purpose, the technical solution adopted by the present invention is:

[0006] A Chinese medicine composition for improving lung injury comprises the following raw materials in parts by weight: 5-20 parts of raw ephedra, 3-12 parts of sophora flavescens, 6-24 parts of bitter almonds, 6-24 parts of bupleurum galbana and 5-20 parts of raw liquorice.

[0007] As a preferred embodiment, the above-mentioned traditional Chinese medicine composition for improving lung injury comprises the following raw materials in parts by weight: 10 parts of raw ephedra, 6 parts of sophora flavescens, 12 parts of bitter almonds, 12 parts of bupleurum galangal, and 10 parts of raw licorice.

[0008] As a preferred embodiment, the above-mentioned Chinese medicine composition for improving lung injury comprises the following raw materials in parts by weight: 15 parts of raw ephedra, 9 parts of sophora flavescens, 18 parts of bitter almonds, 18 parts of bupleurum chinense, and 15 parts of raw licorice.

[0009] As a preferred embodiment, the method for preparing the above-mentioned Chinese medicine composition for improving lung injury comprises the following steps:

[0010] Take raw ephedra, sophora flavescens, bitter almond, bupleurum chinense and raw liquorice according to weight proportions, add water or ethanol to extract, combine the extracts, concentrate and dry to obtain the product.

[0011] As a preferred embodiment, the preparation method of the above-mentioned traditional Chinese medicine composition for improving lung injury comprises the following steps: taking raw ephedra, sophora flavescens, bitter almond, bupleurum chinense, and raw licorice by weight, adding 5 to 15 times the amount of water or 5 to 60% ethanol to the traditional Chinese medicine, extracting 1 to 3 times, each time for 0.5 to 2 hours, combining the extracts, concentrating under reduced pressure, and drying to obtain the extract powder and preparing it into a medicine with a pharmaceutically acceptable carrier.

[0012] As a preferred embodiment, in the method for preparing the above-mentioned Chinese medicinal composition for improving lung injury, the extraction method includes reflux, maceration, percolation or ultrasound.

[0013] As a preferred embodiment, in the method for preparing the above-mentioned Chinese medicinal composition for improving lung injury, the drying method includes air blowing, vacuum or spray drying.

[0014] The extract dry powder of the traditional Chinese medicine composition provided by the present invention and a pharmaceutically acceptable carrier are prepared into medicines, including tablets (dispersible tablets, effervescent tablets, orally disintegrating tablets, lozenges, chewable tablets), capsules (hard capsules, soft capsules), granules, pills, powders, dripping pills, oral liquid preparations, etc.

[0015] The present invention is based on the classic prescription "Sanao Decoction" for restoring lung function, and adds two Ningxia characteristic Chinese medicines, namely, Bupleurum galanga and Sophora flavescens. Raw ephedra, Sophora flavescens, bitter almond, Bupleurum galanga, and raw licorice are selected for compatibility, and the dosage of each medicinal material is determined by the relationship between the effective component and the function, so that the components can act synergistically. In the prescription, ephedra has the effects of sweating and dispelling cold, purifying the lung and relieving asthma, promoting diuresis and reducing swelling, and Sophora flavescens has the effects of clearing heat and drying dampness, antibacterial and anti-inflammatory, anti-tumor, fearing wind and killing insects, and diuresis, which are conducive to reducing lung damage and relieving pulmonary edema, and the two are the main medicines. Bitter almond mainly descends qi, relieves cough and relieves asthma, moistens the intestines and relieves constipation, while Bupleurum galanga clears deficiency heat, clears liver fire, and removes malnutrition heat, and the two are the ministerial medicines. Licorice is added to the prescription to tonify the spleen and replenish qi, clear away heat and detoxify, eliminate phlegm and relieve cough, relieve acute pain, and reconcile various medicines. In the Chinese medicine composition of the present invention, the five-flavor prescription has a wide range of pharmacological activities and has a high application value in treating pulmonary inflammatory diseases.

[0016] The silver bupleurum used in the present invention belongs to the green plant of Caryophyllaceae, which has the effects of clearing away internal heat and eliminating malnutrition and heat. Bupleurum belongs to the plant of Umbelliferae, and silver bupleurum and bupleurum are two different medicinal materials.

[0017] The Chinese medicine compound composition provided by the present invention has a good effect of improving lung injury and can be used to treat acute lung injury. It is convenient to take clinically, and no obvious toxic side effects are found in the Chinese medicine compound composition provided by the present invention during the experiment, and the safety is good. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 Pathological sections showing the effects of each group of optimized Chinese medicine composition on the degree of lung tissue damage in mice with lipopolysaccharide (LPS)-induced acute lung injury.

[0019] Figure 2 This is a bar graph showing the effect of the Chinese medicine composition on the degree of lung tissue damage in mice with acute lung injury induced by lipopolysaccharide (LPS).

[0020] Figure 3 This is a bar graph showing the effect of the Chinese medicine composition on the wet-to-dry ratio of lung tissue in mice with lipopolysaccharide (LPS)-induced acute lung injury.

[0021] Figure 4 This is a bar graph showing the effect of the Chinese medicine composition on the protein concentration of bronchoalveolar lavage fluid in mice with lipopolysaccharide (LPS)-induced acute lung injury.

[0022] Figure 5 This is a bar graph showing the effect of the Chinese medicine composition on the MPO content in lung tissue of mice with acute lung injury induced by lipopolysaccharide (LPS).

[0023] Figure 6 It is a bar graph showing the effect of the Chinese medicine composition on the IL-1β content in the lung tissue of mice with acute lung injury induced by lipopolysaccharide (LPS).

[0024] Figure 7 It is a bar graph showing the effect of the Chinese medicine composition on the IL-6 content in the lung tissue of mice with acute lung injury induced by lipopolysaccharide (LPS).

[0025] Figure 8 It is a bar graph showing the effect of the Chinese medicine composition on the TNF-α content in the lung tissue of mice with acute lung injury induced by lipopolysaccharide (LPS).

[0026] Fig. 9 This is a bar graph showing the effect of the Chinese medicine composition on the IL-1β content in the bronchoalveolar lavage fluid of mice with acute lung injury induced by lipopolysaccharide (LPS).

[0027] Fig.10 This is a bar graph showing the effect of the Chinese medicine composition on the IL-6 content in the bronchoalveolar lavage fluid of mice with acute lung injury induced by lipopolysaccharide (LPS).

[0028] Fig.11 This is a bar graph showing the effect of the Chinese medicine composition on the TNF-α content in the bronchoalveolar lavage fluid of mice with acute lung injury induced by lipopolysaccharide (LPS).

[0029] Fig.12 It is a bar graph showing the effect of the Chinese medicine composition on the IL-1β content in the plasma of mice with acute lung injury induced by lipopolysaccharide (LPS).

[0030] Fig.13 It is a bar graph showing the effect of the Chinese medicine composition on the IL-6 content in the plasma of mice with acute lung injury induced by lipopolysaccharide (LPS).

[0031] Fig.14 It is a bar graph showing the effect of the Chinese medicine composition on the TNF-α content in the plasma of mice with acute lung injury induced by lipopolysaccharide (LPS).

[0032] Fig.15 This is a bar graph showing the effect of the Chinese medicine composition on the degree of lung tissue damage in rats with acute lung injury induced by oleic acid (OA).

[0033] Fig.16 This is a bar graph showing the effects of the Chinese medicine composition on the levels of IL-1β, IL-6, and TNF-α in serum, lung tissue, and bronchoalveolar lavage fluid in rats with acute lung injury induced by oleic acid (OA).

[0034] Fig.17 This is a bar graph showing the effect of the Chinese medicine composition on the levels of SOD, MDA and LDH in the serum of rats with acute lung injury induced by oleic acid (OA). DETAILED DESCRIPTION

[0035] The present invention can be better understood according to the following examples. However, it is easy for those skilled in the art to understand that the specific material ratios, process conditions and results described in the examples are only used to illustrate the present invention, and should not and will not limit the present invention described in detail in the claims.

[0036] Embodiment 1 A method for preparing a Chinese medicine composition for improving lung injury comprises the following steps:

[0037] (1) Take 10 parts of raw ephedra, 6 parts of sophora flavescens, 12 parts of bitter almond, 12 parts of bupleurum chinense, and 10 parts of raw liquorice, mix them, add 10 times the weight of the medicinal materials in water and soak for 30 minutes, boil and decoct for 1 hour, filter and collect the filtrate;

[0038] (2) Take the medicinal residue in step (1), add water in an amount 8 times the weight of the medicinal material, reflux and extract for 1 hour, filter, and collect the filtrate.

[0039] (3) combining the filtrates obtained in step (1) and step (2), concentrating under reduced pressure at 70° C., and vacuum drying the concentrate at 70° C. to obtain a Chinese medicine composition extract.

[0040] (4) Take the extract of the Chinese medicine composition and corn starch, add lubricant magnesium stearate, mix well, and then press into tablets.

[0041] Embodiment 2 A method for preparing a Chinese medicine composition for improving lung injury comprises the following steps:

[0042] (1) Take 20 parts of raw ephedra, 12 parts of sophora flavescens, 24 parts of bitter almond, 24 parts of bupleurum chinense, and 20 parts of raw liquorice, mix them, add 60% ethanol in an amount 12 times the weight of the medicinal materials, reflux and extract for 1 hour, and filter and collect the filtrate;

[0043] (2) Take the medicinal residue in step (1), add 60% ethanol in an amount 10 times the weight of the medicinal material, reflux and extract for 1 hour, filter, and collect the filtrate.

[0044] (3) combining the filtrates obtained in step (1) and step (2), concentrating under reduced pressure at 70° C., and vacuum drying the concentrate at 70° C. to obtain a Chinese medicine composition extract.

[0045] (4) The extract of the Chinese medicine composition is mixed evenly with corn starch, granulated, and then filled into capsules to prepare capsules.

[0046] Example 3 A method for preparing a Chinese medicine composition for improving lung injury comprises the following steps:

[0047] (1) Take 15 parts of raw ephedra, 9 parts of sophora flavescens, 18 parts of bitter almond, 18 parts of bupleurum chinense, and 15 parts of raw liquorice, mix them, add 40% ethanol in an amount 12 times the weight of the medicinal materials, reflux and extract for 2 hours, and filter and collect the filtrate;

[0048] (2) Take the medicinal residue in step (1), add 40% ethanol in an amount 8 times the weight of the medicinal material, reflux and extract for 1 hour, filter, and collect the filtrate.

[0049] (3) combining the filtrates obtained in step (1) and step (2), concentrating under reduced pressure at 70° C., and vacuum drying the concentrate to obtain a Chinese medicine composition extract.

[0050] (4) The extract of the Chinese medicine composition is mixed evenly with corn starch as a diluent, granulated, and dried to prepare granules.

[0051] Example 4 Experimental screening study of Chinese medicine composition for improving lung injury

[0052] 1. Experimental Materials and Drugs

[0053] 1 Experimental animals

[0054] SPF C57BL / 6 mice (male, 6-8 weeks old) were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. (Production License No.: SCXK(Beijing)2021-0006). SPF SD rats were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd., weighing 180-220 g, with production license No. SCXK(Beijing)2021-0011.

[0055] 2 Drugs and reagents

[0056] IL-6 ELISA kit, IL-1β ELISA kit, TNF-α ELISA kit and MPO ELISA kit were purchased from Nanjing Youmeng Biotechnology Co., Ltd. The model drug lipopolysaccharide LPS derived from Escherichia coli O55:B5 was purchased from Sigma-Aldrich. Dexamethasone DEX was purchased from Shanghai Yuanye Biotechnology Co., Ltd. BCA protein assay kit was purchased from Shanghai Biyuntian Biotechnology Co., Ltd. Superoxide dismutase (SOD), malondialdehyde (MDA) and lactate dehydrogenase (LDH) were purchased from Nanjing Jiancheng Biological Company Research Institute.

[0057] Drugs tested:

[0058] Chinese medicine composition extract group 1 (MKD group): the formula is 10 parts of raw ephedra, 6 parts of sophora flavescens, 12 parts of bitter almond, 12 parts of bupleurum galbana, and 10 parts of raw liquorice, prepared according to the method of Example 1;

[0059] Chinese medicine composition extract group 2 (MKD-MH group): the formula is 6 parts of Sophora flavescens, 12 parts of Apricot kernel, 12 parts of Bupleurum galbana, and 10 parts of Licorice root, prepared according to the method of Example 1;

[0060] Chinese medicine composition extract group 3 (MKD-XR group): the formula is 10 parts of raw ephedra, 6 parts of sophora flavescens, 12 parts of bupleurum galbana, and 10 parts of raw liquorice, prepared according to the method of Example 1;

[0061] Chinese medicine composition extract group 4 (MKD-KS group): the formula is 10 parts of raw ephedra, 12 parts of bitter almond, 12 parts of bupleurum galbana, and 10 parts of raw liquorice, prepared according to the method of Example 1;

[0062] Chinese medicine composition extract group 5 (MKD-GC group): the formula is 10 parts of raw ephedra, 6 parts of sophora flavescens, 12 parts of bitter apricot kernel, and 12 parts of bupleurum galbana, prepared according to the method of Example 1;

[0063] Chinese medicine composition extract group 6 (MKD-YCH group): the formula is 10 parts of raw ephedra, 6 parts of sophora flavescens, 12 parts of bitter almonds, and 10 parts of raw liquorice, which is prepared according to the method of Example 1.

[0064] 3 Instruments

[0065] PL511402 ultrapure water system (USF, USA); Anke GL-16G centrifuge (Shanghai Anting Scientific Instrument Factory); Enspire multifunctional microplate reader (Perkin Elmer, USA); blast drying oven (Yiheng Scientific Instrument Co., Ltd., DHG-9240A); fully automatic sample rapid grinding instrument (Shanghai Jingyexin Development Co., Ltd.)

[0066] 2. Experimental Methods

[0067] 1. Establishment of LPS-induced acute lung injury mouse model and optimization of Chinese medicine composition

[0068] After one week of adaptation to the new environment, the mice were randomly divided into 9 groups, 6 mice in each group, blank group; model group; DEX group; Chinese herbal medicine extract group 1 (MKD group); Chinese herbal medicine extract group 2 (MKD-MH group); Chinese herbal medicine extract group 3 (MKD-XR group); Chinese herbal medicine extract group 4 (MKD-KS group); Chinese herbal medicine extract group 5 (MKD-GC group); Chinese herbal medicine extract group 6 (MKD-YCH group). Except for the blank group mice, which were anesthetized and instilled with PBS through the trachea, the mice in the other groups were anesthetized and LPS dissolved in phosphate buffered saline (PBS) was administered orally through the trachea (IT, 5 mg / kg). After waking up from anesthesia, the mice in the blank group and the model group were gavaged with normal saline every day; the DEX group was gavaged with dexamethasone; the drug-treated groups were all administered with the tested Chinese herbal extracts 1 to 6 at a dose of 19.5 g / kg. After 3 consecutive days of drug administration, the mice were killed by sodium pentobarbital anesthesia, and the lung tissues were collected for HE staining, and the sections were pathologically analyzed to observe the therapeutic effects of each group.

[0069] 3. Experimental Results

[0070] Depend on Figure 1 Observation of lung tissue pathological sections showed that the alveolar wall of the model group mice lung tissue was thickened, neutrophil infiltration was seen in the alveolar wall congestion, compensatory alveolar enlargement, bronchial epithelial cell shedding, and irregular cell arrangement. Compared with the model group, each medication group alleviated the lung damage of mice caused by LPS to varying degrees. Among them, the MKD group had the most significant effect in improving acute lung injury. The improvement degrees of other medication groups were MKD-YCH group, MKD-GC group, MKD-XR group, MKD-KS group, and MKD-MH group, respectively. Therefore, the MKD Chinese medicine composition is preferred.

[0071] Example 5 Experimental study on improving lung injury

[0072] 1. Experimental Materials and Drugs

[0073] 1 Experimental animals

[0074] SPF C57BL / 6 mice (male, 6-8 weeks old) were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. (Production License No.: SCXK(Beijing)2021-0006). SPF SD rats were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd., weighing 180-220 g, with production license No. SCXK(Beijing)2021-0011.

[0075] 2 Drugs and reagents

[0076] IL-6 ELISA kit, IL-1β ELISA kit, TNF-α ELISA kit and MPO ELISA kit were purchased from Nanjing Youmeng Biotechnology Co., Ltd. The model drug lipopolysaccharide LPS derived from Escherichia coli O55:B5 was purchased from Sigma-Aldrich. Dexamethasone DEX was purchased from Shanghai Yuanye Biotechnology Co., Ltd. BCA protein assay kit was purchased from Shanghai Biyuntian Biotechnology Co., Ltd. Superoxide dismutase (SOD), malondialdehyde (MDA) and lactate dehydrogenase (LDH) were purchased from Nanjing Jiancheng Biological Company Research Institute.

[0077] Test drug: the extract of the Chinese medicine composition prepared in Example 1 of the present invention.

[0078] 3 Instruments

[0079] PL511402 ultrapure water system (USF Company, USA); Anke GL-16G centrifuge (Shanghai Anting Scientific Instrument Factory); Enspire multifunctional microplate reader (Perkin Elmer Company, USA); blast drying oven (Yiheng Scientific Instrument Co., Ltd., DHG-9240A); fully automatic sample rapid grinding instrument (Shanghai Jingyexin Development Co., Ltd.).

[0080] 2. Experimental Methods

[0081] 1. Establishment and administration of lipopolysaccharide (LPS)-induced acute lung injury mouse model

[0082] After one week of adaptation to the new environment, the mice were randomly divided into 5 groups, 6 mice in each group: blank group; model group; DEX group; low-dose group of Chinese medicine composition extract (MKD-L group); high-dose group of Chinese medicine composition extract (MKD-H group). Except for the blank group mice, which were anesthetized and instilled with PBS through the trachea, the mice in the other groups were anesthetized and LPS (IT, 5 mg / kg) dissolved in phosphate buffered saline (PBS) was administered through the mouth and trachea. After waking up from anesthesia, the blank group and model group mice were gavaged with normal saline every day; the DEX group was gavaged with dexamethasone; the MKD-L group and the MKD-H group were administered with the tested Chinese medicine composition Example 1 at a dose of 6.5 g / kg and 19.5 g / kg, respectively. After the mice were continuously administered for 3 days, they were killed by sodium pentobarbital anesthesia, and plasma, bronchoalveolar lavage fluid (BALF) and lung tissue were collected for further examination.

[0083] 2. Establishment and administration of oleic acid (OA)-induced acute lung injury rat model

[0084] 180-220g SD rats were selected, and after one week of adaptive feeding, they were randomly divided into a blank group, a model group, a positive drug group (dexamethasone), and a drug administration group according to their body weight. Example 1 Chinese medicine composition extract administration group, each group was respectively provided with three doses (MXKGD-H, MXKGD-M, MXKGD-L) of high (18g / kg), medium (9g / kg), and low (4.5g / kg), 10 rats in each group (6 groups in total). Except for the blank group and the model group rats gavaged with normal saline, the remaining groups of rats were gavaged with the corresponding drugs for 7 consecutive days. The positive drug group was the positive drug dexamethasone. After the last administration, the blank group was injected with normal saline by tail vein, and the model group and the drug administration group were injected with oleic acid (100mg / kg) by tail vein to form an acute lung injury model, and the rats were dissected and taken after 12h of modeling.

[0085] 3. Efficacy evaluation method

[0086] After the last administration of the experimental animals in each group, the animals were anesthetized with sodium pentobarbital and killed. Plasma, bronchoalveolar lavage fluid (BALF) and lung tissue were collected for HE staining section scoring and detection of IL-6, IL-1β, TNF-α, SOD, LDH and MDA.

[0087] 4. Statistical analysis

[0088] All experimental data were statistically analyzed using Graph Pad Prism 8 software. One-way ANOVA and Kruskl-Wallis test were used for comparison among groups. The differences were considered statistically significant when P < 0.05.

[0089] Depend on Figure 2-Figure 14It can be seen that compared with the control group, the LPS-induced model group mice had obvious lung tissue damage, increased lung wet-to-dry ratio and protein content in BALF, significantly increased lung MPO levels, and significantly increased levels of three proinflammatory cytokines in plasma, BALF and lung, indicating that the model group mice had obvious successful modeling of lung inflammation. After administration of the Chinese medicine composition, the degree of lung tissue damage, lung wet-to-dry ratio and protein content in BALF, lung MPO levels, and levels of three proinflammatory cytokines in BALF and lung were significantly reduced (P<0.05).

[0090] Depend on Fig.15 It can be seen that the lung tissue of rats in the model group induced by oleic acid (OA) was significantly damaged, and the degree of lung tissue damage was significantly improved after administration of the Chinese medicine composition (P<0.05). Compared with the blank group, the expression of TNF-α, IL-1β, and IL-6 in the model group increased significantly (P<0.01). After administration of the Chinese medicine composition, the high-dose group could significantly reduce the levels of inflammatory factors in serum and lungs (P<0.01), and the medium and high-dose groups could significantly reduce the levels of inflammatory factors in BALF (P<0.05). Fig.16 As shown. The results of oxidative stress index analysis showed that the levels of MPO, superoxide dismutase (SOD), malondialdehyde (MDA), and lactate dehydrogenase (LDH) in the model rats increased significantly (P<0.05). After administration of the Chinese medicine composition, the medium and high dose groups could significantly reduce the levels of MPO and SOD (P<0.05), and each dose group could significantly reduce the levels of MDA and LDH in rats (P<0.05) ( Fig.17 ).

[0091] In summary, the Chinese medicine composition provided by the present invention has good effects of reducing lung damage, relieving pulmonary edema, anti-inflammation and anti-oxidative stress. It has good therapeutic effect and safety, can be used for the treatment of acute lung injury, and has high drug development value.

[0092] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A Chinese medicine composition for improving lung injury, characterized in that: The invention comprises the following raw materials in parts by weight: 5-20 parts of raw ephedra, 3-12 parts of sophora flavescens, 6-24 parts of bitter almond, 6-24 parts of bupleurum galbana and 5-20 parts of raw liquorice.

2. The Chinese medicine composition for improving lung injury according to claim 1, characterized in that: The invention comprises the following raw materials in parts by weight: 10 parts of raw ephedra, 6 parts of sophora flavescens, 12 parts of bitter almond, 12 parts of bupleurum galangal and 10 parts of raw liquorice.

3. The Chinese medicine composition for improving lung injury according to claim 1, characterized in that: The invention comprises the following raw materials in parts by weight: 15 parts of raw ephedra, 9 parts of sophora flavescens, 18 parts of bitter almond, 18 parts of bupleurum chinense and 15 parts of raw liquorice.

4. The method for preparing the Chinese medicine composition for improving lung injury according to any one of claims 1 to 3, characterized in that: It includes the following steps: Take raw ephedra, sophora flavescens, bitter almond, bupleurum chinense and raw liquorice according to weight proportions, add water or ethanol to extract, combine the extracts, concentrate and dry to obtain the product.

5. The method for preparing the Chinese medicine composition for improving lung injury according to claim 4, characterized in that: The method comprises the following steps: taking raw ephedra, sophora flavescens, bitter almond, bupleurum galanga and raw liquorice according to weight proportions, adding 5-15 times amount of water or 5-60% ethanol to the Chinese medicinal materials for extraction for 1 to 3 times, each time for 0.5 to 2 hours, combining the extracts, concentrating under reduced pressure, drying to obtain the extract powder and preparing the medicine with a pharmaceutically acceptable carrier.

6. The method for preparing the Chinese medicine composition for improving lung injury according to claim 5, characterized in that: Extraction methods include reflux, maceration, percolation or sonication.

7. The method for preparing the Chinese medicine composition for improving lung injury according to claim 5, characterized in that: Drying methods include air-blast, vacuum or spray drying.

8. The method for preparing a Chinese medicinal compound composition for improving lung injury according to claim 5, characterized in that: The preparations include tablets, capsules, granules, pills, powders, dripping pills, and oral liquid preparations.

9. Use of the Chinese medicine composition according to any one of claims 1 to 3 in the preparation of a drug for improving lung injury diseases.

10. Use of the Chinese medicine composition according to any one of claims 1 to 3 in the preparation of a drug for improving acute lung injury.

Images